Tagged with Manufacturing,

Dominican Republic The rise of the Dominican Republic as a regional medtech manufacturing hub might have come as a surprise to many, but not to the insiders and executives of the Central America & Caribbean healthcare industry. With several decades of economic growth and political stability, the country has positioned itself as…

Australia Regular PharmaBoardroom contributor Brendan Shaw outlines how his home country of Australia has so far successfully managed to avoid the worst of the COVID-19 pandemic, providing opportunities for the life sciences industry to invest in new facilities, research and development in a post-pandemic world.   Australia, the island continent A…

Switzerland Susanne Caspar, CEO at Swiss natural API producer Linnea, talks about her first few months in the company, the pharmaceutical industry’s growing embrace of natural ingredients, and why Linnea has made the move into cannabis API production.   2020 was defined by an increase in demand for dietary supplements because…

Switzerland Swiss-headquartered ADIENNE has made recent headlines after being announced as the first European company to manufacture Russia’s Sputnik V COVID-19 vaccine. President and Founder Antonio Francesco Di Naro explains how the company’s deal with the Russian Direct Investment Fund happened and some of the challenges related to the manufacturing process.…

Switzerland In the last month alone, CDMO giant Lonza has announced three major upgrades to its manufacturing footprint in Visp, Western Switzerland: a huge expansion of its biologics capacity, new production lines for the manufacture of antibody-drug conjugates, and a ramping up of its workforce dedicated to the production of ingredients…

China Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of the largest Contract Research, Development and Manufacturing organizations (CRDMOs) in the world, his talent strategy, and the use of AI within the sector.   BioDuro has very strong capabilities on the discovery…

Global As the global pharmaceutical industry continues to grow, so have opportunities for service providers. Over the last few decades, while big pharma companies continued to focus on their core business, contract development and manufacturing organizations (CDMOs) have positioned themselves as alternatives to in-house development and manufacturing operations, promising to decrease…

Switzerland Alvotech – the biosimilars arm of Icelandic-headquartered generics player Alvogen – is positioning itself for future growth via a very different strategy to that of the Big Pharma players with biosimilar portfolios. Chief Commercial Officer Anil Okay, who sits in Switzerland, explains the four company traits that he believes will…

Switzerland CCO Anil Okay introduces how Alvotech’s focus on biosimilars, comprehensive platform, differentiated portfolio approach, and commercial strategy differentiates the company and allows it to compete with the Big Pharma players also present in the biosimilars space.   We position ourselves as a pure play, differentiated, fully vertically integrated biosimilars development…

Switzerland Chief Financial Officer Marina Lugova introduces pharmaceutical company Synbias Pharma’s evolving European footprint, how the company has been able to withstand the COVID-19 pandemic and continue providing its essential products to customers, and its plans for the future, including further investments in the firm’s German production facility and new strategic…

Europe On 25 November, the European Commission adopted a new strategy meant to, among others, allow Europe to cover its pharmaceutical needs, including in times of crisis, through robust supply chains. The strategy also contains a flagship actions to help curb the rise of antimicrobial resistance. Rex Clements, CEO of Centrient…

USA Joe Lewis outlines the key concerns of Deloitte’s pharma clients around manufacturing and supply chain operations in the wake of the COVID-19 pandemic, how companies can come out of the crisis stronger, and highlights some of the major issues surrounding vaccine allocation and deployment.   One of the most common…